Recently Featured

Biogen Expands Immunology Portfolio with $5.6B Acquisition of Apellis

April 2, 2026
Biogen has announced its acquisition of Apellis Pharmaceuticals for $5.6 billion, a strategic move that significantly enhances its immunology portfolio. This deal not only secures two marketed products, Syfovre and Empaveli, but also brings in a specialized team with extensive nephrology expertise. As Biogen gears up to launch felzartamab, the addition of Apellis’ resources and…

Iterum Initiates Wind-Down After Failure to Offload Antibiotic with Sluggish Sales

April 1, 2026
Irish antibiotic specialist Iterum Therapeutics has announced the initiation of a wind-down of its operations due to limited cash reserves and the costly commercialization efforts surrounding its sole approved product, Orlynvah. This decision follows the company’s unsuccessful attempts to divest the antibiotic, which has struggled to gain traction in a competitive market. The context of…

Avo Secures $10 Million to Enhance Physician Workflow Efficiency

April 1, 2026
Avo, a startup leveraging patient health records to streamline administrative tasks for physicians, has successfully raised $10 million in funding, as reported exclusively by Endpoints News. This financial boost is aimed at enhancing Avo’s innovative platform, which assists doctors in managing paperwork and making informed decisions during patient visits. The significance of this funding lies…

Ongoing Cases